CEDAR KNOLLS, N.J.,
June 18, 2019 /PRNewswire/
-- MYOS RENS Technology Inc. ("MYOS" or "the Company")
(NASDAQ: MYOS), an advanced nutrition company and the owner of
Fortetropin®, a proprietary bioactive composition
derived from fertilized egg yolk that helps build lean
muscle, announced today positive
top-line results from a randomized, double-blind,
placebo-controlled study that was conducted at the University of California, Berkeley and the
University of Arkansas for Medical
Sciences evaluating the impact of Fortetropin on the rate of muscle
protein synthesis in older men and women (60-75 years of
age).
In this randomized, double-blind, placebo-controlled clinical
study, 20 subjects, men and women 60 to 75 years of age, were
assigned to consume either Fortetropin or a macronutrient-matched
placebo for 21 days along with daily doses of a heavy water
tracer. After 21 days, a microbiopsy was collected from each
subject and analyzed to determine the fractional synthetic rate
(FSR) of muscle proteins. For subjects who received
Fortetropin, the average FSR in several gene ontologies were
significantly higher compared to the placebo group. The
proportion of proteins with an increased FSR in the Fortetropin
group (33/38 myofibril proteins, 36/44 cytoplasmic proteins and
15/19 mitochondrial proteins) relative to the placebo group was
found to be statistically significant.
Muscle loss represents one of the most important causes of
functional decline and loss of independence in older adults.
Age-related muscle loss (sarcopenia) is commonly observed in
many older adults and is also characterized by a decrease in the
rate of muscle protein synthesis. In addition, low muscle mass is
associated with fall-related injuries which can be devastating to
adults over the age of 60 years, particularly if they result in a
bone fracture. In this study, Fortetropin was shown to
improve the average muscle protein synthesis rate, providing the
potential to improve muscle health among older adults. There are
very limited options available to address age-related muscle
loss. Geriatricians commonly manage this through lifestyle
interventions such as diet and exercise.
"We believe the results from the UC Berkeley clinical study show
that our all-natural ingredient Fortetropin can significantly
improve muscle health for older adults," commented Joseph Mannello, CEO of MYOS RENS
Technology. "We are committed to continuing scientific
research to demonstrate the efficacy of our advanced nutrition
products. This study shows Fortetropin's remarkable potential
for managing age-related muscle loss in older adults. The
results from this study will form the cornerstone of MYOS' 'Healthy
Aging' business unit. The global elderly nutrition market was
$19B in 2018 and is estimated to
surpass $31B by 2026. We plan to
aggressively move forward with additional clinical studies that
will focus on this area along with recovery and
rehabilitation."
"The results from this clinical study evaluating the impact of
Fortetropin on muscle protein synthesis rates in older adults are
very exciting," commented the Principal Investigator, William J. Evans, Ph.D., Adjunct Professor of
Human Nutrition, University of California,
Berkeley and an expert in sarcopenia. "Fortetropin
clearly has a robust effect on the rate of muscle protein synthesis
in older adults. It is rare for a nutrition product to show
such a consistent and positive effect. We look forward to
continued scientific collaboration with MYOS."
Conference Call Details:
Call Date/Time: Wednesday, June 19,
2019 at 11:00 am ET
Dial In: 877-407-4019 from the U.S.; international callers may
telephone 201-689-8337, approximately 10 minutes before the
call.
A digital replay will be available by telephone approximately
two hours after the completion of the call until September 19, 2019 and may be accessed by dialing
877-660-6853 from the U.S. or 201-612-7415 for international
callers, using the Conference ID# 13691863.
This call will be simultaneously webcast. The webcast will be
available on the MYOS website, www.myosrens.com, in the "Investor
Relations" section. The webcast will be archived and available at
the same web address for two weeks following the call.
About Fortetropin®
Fortetropin is a
proprietary composition made from fertilized egg yolk through a
patented process that maintains its vital nutrients and bioactivity
to build more lean muscle and decrease muscle loss. It is the main
ingredient in Yolked® muscle health
formula, an NSF Certified for Sport® all-natural
sports nutrition product that helps your body utilize protein more
efficiently to build more lean muscle in conjunction with
resistance training, and in Myos Canine Muscle
Formula, the first product of its kind to support muscle
health in dogs. For more information please visit www.yolked.com
and/or www.myospet.com.
About MYOS RENS Technology Inc.
MYOS RENS
Technology Inc. (MYOS), "The Muscle Company®", is a
Cedar Knolls, NJ-based advanced
nutrition company that develops and markets products that improve
muscle health and performance. MYOS is the owner of
Fortetropin®, a fertilized egg yolk-based product
manufactured via a proprietary process to retain and optimize its
biological activity. Fortetropin has been clinically shown to
increase muscle size and lean body mass in conjunction with
resistance training. MYOS believes Fortetropin has the potential to
redefine existing standards of physical health and wellness. For
more information, please visit www.MYOSRENS.com.
Forward-Looking Statements
Any statements in
this release that are not historical facts are forward-looking
statements. Actual results may differ materially from those
projected or implied in any forward-looking statements. Such
statements involve risks and uncertainties, including but not
limited to those relating to product and customer demand, market
acceptance of our products, the ability to create new products
through research and development, the successful results of
strategic initiatives, the success of our products, including
Qurr®, Yolked®, MYOS Enteral
Nutrition Formula™ and MYOS Canine Muscle
Formula® , the success of our research and
development, the results of the clinical evaluation
of Fortetropin® and its effects,
including the results of the clinical study described in this
release, the ability to enter into new partnership opportunities
and the success of our existing partnerships, the ability to
generate revenue and cash flow from sales of our products, the
ability to increase our revenue and gross profit margins, the
ability to achieve a sustainable, profitable business, the effect
of economic conditions, the ability to protect our intellectual
property rights, competition from other providers and products, the
continued listing of our securities on the Nasdaq Stock Market,
risks in product development, our ability to raise capital to fund
continuing operations, and other factors discussed from time to
time in our filings with the Securities and Exchange
Commission. We undertake no obligation to update or revise any
forward-looking statement for events or circumstances after the
date on which such statement is made except as required by
law.
These statements have not been evaluated by the Food and Drug
Administration. Our products are not intended to diagnose, treat,
cure or prevent any disease.
Investor Relations:
Porter LeVay & Rose
Matthew Abenante, IRC, SVP
Phone: 212-564-4700
Email: MYOS@plrinvest.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/myos-rens-fortetropin-shown-to-increase-the-rate-of-muscle-protein-synthesis-in-older-adults-in-clinical-study-carried-out-at-university-of-california-berkeley-300870870.html
SOURCE MYOS RENS Technology Inc.